-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompileDraven
The state of Arkansas has taken Eli Lilly, Novo Nordisk, Sanofi and three major Pharmacy Benefits Managers (PBMs) to court, accusing them of conspiring to raise the price of insulin and other diabetes-related dru.
This is not the first time that Sanofi, Eli Lilly and Novo Nordisk have been collectively su.
More than 400,000 people in Arkansas have been diagnosed with diabetes and more than 800,000 people are prediabet.
In the lawsuit, Arkansas Attorney General Leslie Rutledge said drug companies have simultaneously raised the prices of their diabetes drugs over the past 15 yea.
The three PBMs listed in the lawsuit—CVS Caremark, Express Scripts, and OptumRx—control 80 percent of the.
The lawsuit alleges that the Big Three Pharma and the Big Three PBMs violated the Arkansas Deceptive Trade Practices Act (ADTPA) with unjust enrichment and civil conspiracy, and as such, are subject to civil penalties, damages, e.
In fact, rising insulin prices have been one of the "stubborn ailments" at the center of many lawsuits over the yea.
So far, Eli Lilly, Novo Nordisk and Sanofi have not responded to the lawsu.
Reference source:
Former Immunomedics CFO Usama Malik indicted for insider trading, pledging to dispute 'false and speculative narrative' at trial
